12:00 AM
 | 
Mar 04, 2013
 |  BioCentury  |  Finance

Easy on the eyes

Kala series A funds to advance mucosal delivery technology in ophthalmics
Easy on the eyes

Kala Pharmaceuticals Inc.'s $11.5 million series A round should allow the company to move its mucosal penetrating particle technology into the clinic for an ophthalmic indication.

New investor Crown Venture Fund led the round, in which existing investors Lux Capital, Polaris and Third Rock Ventures also participated. Kala raised $11.2 million in a seed round in 2012.

The mucosal penetrating particle technology is based on IP from...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >